Bogart Wealth’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Bogart Wealth's CRSP Position: Q3 2026 in Review
Bogart Wealth held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 150 shares worth $8.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1067.
Bogart Wealth first reported a position in CRSP in Q3 2022 and has held it in 12 quarters since. The position peaked at $42.1K in Q3 2025. 502 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Bogart Wealth held 150 shares of CRISPR Therapeutics worth $8.3K as of Q3 2026.
- Bogart Wealth left its CRISPR Therapeutics share count unchanged in Q3 2026.
- CRISPR Therapeutics made up ﹤0.01% of Bogart Wealth's portfolio in Q3 2026, its #1067 holding.
- Bogart Wealth first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 12 quarters since.
- Bogart Wealth's CRISPR Therapeutics position peaked at $42.1K in Q3 2025.
- 502 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Bogart Wealth's 13F filing for Q3 2026, filed 10 Nov 2026.